Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.49 |
| ▸ | FAAH | O00519 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | AADAC | P22760 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11954001 | 0.82 | GPR119 (0.51) | EPHX1EPHX2FAAHKCNH2 | |
| SCHEMBL943416 | 0.81 | KCNH2 (0.52) | EPHX1KCNH2HRH1 | |
| SCHEMBL6698284 | 0.78 | NAMPT (0.56) | — | |
| SCHEMBL8799332 | 0.78 | KCNH2 (0.49) | KCNH2HRH1 | |
| SCHEMBL8799456 | 0.78 | HRH3 (0.49) | KCNH2HRH1 | |
| Trifluoroacetic Acid SCHEMBL2823895 | 0.76 | HRH1 (0.53) | EPHX1EPHX2KCNH2HRH1 | |
| SCHEMBL1673897 | 0.76 | HRH1 (0.59) | EPHX1EPHX2FAAHAADACHRH1 | |
| SCHEMBL5839598 | 0.75 | GBA1 (0.47) | EPHX1EPHX2 | |
| SCHEMBL1870322 | 0.75 | NPC1 (0.57) | EPHX1EPHX2KCNH2HRH1 | |
| Trifluoroacetic Acid SCHEMBL4233307 | 0.74 | EPHX2 (0.50) | EPHX2KCNH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440052-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | UNIV OF OULU (FI) | 2023-10-25 | — | — | EP | disclosed |
| US-20210346322-A1 | Compounds for use in the treatment of cancer | UNIVERSITY OF OULU (FI) | 2021-11-11 | — | — | US | disclosed |
| US-20190105289-A1 | Compounds for use in the treatment of cancer | UNIVERSITY OF OULU (FI) | 2019-04-11 | — | — | US | disclosed |
| EP-3440052-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | University Of Oulu (FI) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174879-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITY OF OULU (FI) | 2017-10-12 | — | — | WO | disclosed |
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346322-A1 | Compounds for use in the treatment of cancer | PARP10, MACROD1, MACROD2 | EPHX1 2159/4885EPHX2 2711/4885FAAH 3266/4885 |
| US-20190105289-A1 | Compounds for use in the treatment of cancer | PARP10, MACROD1, MACROD2 | EPHX1 2159/4885EPHX2 2711/4885FAAH 3266/4885 |
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | EPHX1 1073/4885EPHX2 1186/4885FAAH 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.